---
document_datetime: 2025-12-02 05:45:13
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/litak.html
document_name: litak.html
version: success
processing_time: 0.1186992
conversion_datetime: 2025-12-27 14:27:19.98933
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Litak

[RSS](/en/individual-human-medicine.xml/66934)

##### Authorised

This medicine is authorised for use in the European Union

cladribine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information about Litak](#more-information-about-litak-828)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

Expand section

Collapse section

## What is Litak?

Litak is a solution for injection that contains the active substance cladribine.

## What is Litak used for?

Litak is used to treat adults with hairy-cell leukaemia, a cancer of blood in which too many B-lymphocytes (a type of white blood cell) are produced. The term 'hairy cell' refers to the hair-like projections that can be seen on the surface of the lymphocytes when they are examined under a microscope.

Because the number of patients with hairy-cell leukaemia is low, the disease is considered 'rare', and Litak was designated an 'orphan medicine' (a medicine used in rare diseases) on 18 September 2001.

The medicine can only be obtained with a prescription.

## How is Litak used?

Litak treatment should be started by a doctor who has experience in the use of cancer treatments. Litak is given as an injection under the skin. The recommended dose is 0.14 mg per kilogram body weight, once a day for five days. Patients can inject themselves once they have been trained appropriately. Litak must not be given to patients with moderate to severe liver or kidney disease. It should be used with caution in patients over 65 years of age, with frequent monitoring of blood counts, the liver and the kidneys.

## How does Litak work?

The active substance in Litak, cladribine, is a cytotoxic, a medicine that kills cells that are dividing, such as cancer cells. It belongs to the group of anticancer medicines called 'antimetabolites'. Cladribine is an 'analogue' of purine (a substance that has a similar chemical structure to purine). Purine is one of the fundamental chemicals that make up DNA. In the body, cladribine is converted within lymphocytes into a chemical called CdATP, which interferes with the production of new DNA. This prevents the cells from dividing, slowing down the progression of leukaemia. CdATP can also affect other cells, particularly other types of blood cell, which can cause side effects.

Cladribine has been in use in anticancer medicines since the 1980s and it has been available as an intravenous infusion (drip into a vein) in some European Union (EU) Member States since 1993.

## How has Litak been studied?

Because cladribine has been used for a number of years, the company presented data from the published literature. Litak has been examined in one main study involving 63 adults with hairy-cell leukaemia. Litak was not compared with any other treatments in this study. The main measures of effectiveness were the numbers of patients who had complete and partial remission following treatment. Complete remission is the disappearance of all evidence of disease, whereas partial remission is improved blood counts and the reduction in the number of cancerous cells.

## What benefit has Litak shown during the studies?

In the main study, 97% of the patients had either complete or partial remission (60 out of 62), and 76% had complete remission (47 out of 62). These results were similar to those seen in other published studies using intravenous cladribine and were better than results seen with alternative treatments such as interferon alfa and pentostatin.

## What is the risk associated with Litak?

The most common side effects with Litak (seen in more than 1 patient in 10) are infections, pancytopenia or myelosuppression (low blood cell counts), purpura (bruising), immunosuppression (a weakened immune system), decreased appetite, headache, dizziness, abnormal breath and chest sounds, cough, nausea (feeling sick), vomiting, constipation, diarrhoea, rash, localised exanthema (skin eruptions), diaphoresis (excessive sweating), injection-site reactions (pain and inflammation at the site of injection), fever, fatigue (tiredness), chills and asthenia (weakness). For the full list of all side effects reported with Litak, see the package leaflet.

Litak should not be used in people who may be hypersensitive (allergic) to cladribine or any of the other ingredients. Litak must not be used during pregnancy or breast-feeding, in patients less than 18 years of age, in patients with moderate to severe kidney or liver disease or in combination with other medicines that reduce the production of blood cells.

## Why has Litak been approved?

The Committee for Medicinal Products for Human Use (CHMP) decided that Litak's benefits are greater than its risks for the treatment of hairy-cell leukaemia. The Committee recommended that Litak be given marketing authorisation.

## Other information about Litak:

The European Commission granted a marketing authorisation valid throughout the EU for Litak to Lipomed GmbH on 14 April 2004. The marketing authorisation was renewed on 14 April 2009.

Litak : EPAR - Summary for the public

English (EN) (43.8 KB - PDF)

**First published:** 03/06/2006

**Last updated:** 03/06/2006

[View](/en/documents/overview/litak-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-134)

български (BG) (169.4 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/bg/documents/overview/litak-epar-summary-public_bg.pdf)

español (ES) (45.1 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/es/documents/overview/litak-epar-summary-public_es.pdf)

čeština (CS) (161.25 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/cs/documents/overview/litak-epar-summary-public_cs.pdf)

dansk (DA) (44.62 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/da/documents/overview/litak-epar-summary-public_da.pdf)

Deutsch (DE) (45.6 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/de/documents/overview/litak-epar-summary-public_de.pdf)

eesti keel (ET) (44.24 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/et/documents/overview/litak-epar-summary-public_et.pdf)

ελληνικά (EL) (164 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/el/documents/overview/litak-epar-summary-public_el.pdf)

français (FR) (44.98 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/fr/documents/overview/litak-epar-summary-public_fr.pdf)

italiano (IT) (44.89 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/it/documents/overview/litak-epar-summary-public_it.pdf)

latviešu valoda (LV) (163.1 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/lv/documents/overview/litak-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (157.45 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/lt/documents/overview/litak-epar-summary-public_lt.pdf)

magyar (HU) (153.16 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/hu/documents/overview/litak-epar-summary-public_hu.pdf)

Malti (MT) (162.86 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/mt/documents/overview/litak-epar-summary-public_mt.pdf)

Nederlands (NL) (44.9 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/nl/documents/overview/litak-epar-summary-public_nl.pdf)

polski (PL) (168.17 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/pl/documents/overview/litak-epar-summary-public_pl.pdf)

português (PT) (45.47 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/pt/documents/overview/litak-epar-summary-public_pt.pdf)

română (RO) (152.31 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/ro/documents/overview/litak-epar-summary-public_ro.pdf)

slovenčina (SK) (158.28 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/sk/documents/overview/litak-epar-summary-public_sk.pdf)

slovenščina (SL) (148.74 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/sl/documents/overview/litak-epar-summary-public_sl.pdf)

Suomi (FI) (44.51 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/fi/documents/overview/litak-epar-summary-public_fi.pdf)

svenska (SV) (44.56 KB - PDF)

**First published:**

03/06/2006

**Last updated:**

03/06/2006

[View](/sv/documents/overview/litak-epar-summary-public_sv.pdf)

## Product information

Litak : EPAR - Product Information

English (EN) (202.86 KB - PDF)

**First published:** 14/07/2009

**Last updated:** 03/04/2025

[View](/en/documents/product-information/litak-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-872)

български (BG) (355.68 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/bg/documents/product-information/litak-epar-product-information_bg.pdf)

español (ES) (210.63 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/es/documents/product-information/litak-epar-product-information_es.pdf)

čeština (CS) (352.4 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/cs/documents/product-information/litak-epar-product-information_cs.pdf)

dansk (DA) (202.93 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/da/documents/product-information/litak-epar-product-information_da.pdf)

Deutsch (DE) (210.98 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/de/documents/product-information/litak-epar-product-information_de.pdf)

eesti keel (ET) (202.78 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/et/documents/product-information/litak-epar-product-information_et.pdf)

ελληνικά (EL) (342.24 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/el/documents/product-information/litak-epar-product-information_el.pdf)

français (FR) (206.67 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/fr/documents/product-information/litak-epar-product-information_fr.pdf)

hrvatski (HR) (328.11 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/hr/documents/product-information/litak-epar-product-information_hr.pdf)

íslenska (IS) (196.64 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/is/documents/product-information/litak-epar-product-information_is.pdf)

italiano (IT) (219.45 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/it/documents/product-information/litak-epar-product-information_it.pdf)

latviešu valoda (LV) (327.45 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/lv/documents/product-information/litak-epar-product-information_lv.pdf)

lietuvių kalba (LT) (328.16 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/lt/documents/product-information/litak-epar-product-information_lt.pdf)

magyar (HU) (337.02 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/hu/documents/product-information/litak-epar-product-information_hu.pdf)

Malti (MT) (370.15 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/mt/documents/product-information/litak-epar-product-information_mt.pdf)

Nederlands (NL) (194.64 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/nl/documents/product-information/litak-epar-product-information_nl.pdf)

norsk (NO) (188.49 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/no/documents/product-information/litak-epar-product-information_no.pdf)

polski (PL) (336.14 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/pl/documents/product-information/litak-epar-product-information_pl.pdf)

português (PT) (204.73 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/pt/documents/product-information/litak-epar-product-information_pt.pdf)

română (RO) (347.45 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/ro/documents/product-information/litak-epar-product-information_ro.pdf)

slovenčina (SK) (319.94 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/sk/documents/product-information/litak-epar-product-information_sk.pdf)

slovenščina (SL) (310.94 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/sl/documents/product-information/litak-epar-product-information_sl.pdf)

Suomi (FI) (199.69 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/fi/documents/product-information/litak-epar-product-information_fi.pdf)

svenska (SV) (195.1 KB - PDF)

**First published:**

14/07/2009

**Last updated:**

03/04/2025

[View](/sv/documents/product-information/litak-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00000787/202402 19/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Litak : EPAR - All Authorised presentations

English (EN) (58.29 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_en.pdf)

[Other languages (22)](#file-language-dropdown-585)

български (BG) (85.34 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/bg/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_bg.pdf)

español (ES) (45.1 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/es/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_es.pdf)

čeština (CS) (78.3 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/cs/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (58.96 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/da/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (61.64 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/de/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (54.22 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/et/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (72.33 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/el/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_el.pdf)

français (FR) (56.38 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fr/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (73.11 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/hr/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_hr.pdf)

italiano (IT) (55.26 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/it/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (69.84 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lv/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (59.25 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/lt/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (76.9 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/hu/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (85.73 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/mt/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (56.86 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/nl/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_nl.pdf)

polski (PL) (79.38 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pl/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_pl.pdf)

português (PT) (58.5 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/pt/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_pt.pdf)

română (RO) (85.32 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/ro/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (68.74 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sk/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (66.98 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sl/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (53.52 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/fi/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (56.97 KB - PDF)

**First published:**

21/10/2005

**Last updated:**

21/10/2005

[View](/sv/documents/all-authorised-presentations/litak-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Litak Active substance Cladribine International non-proprietary name (INN) or common name cladribine Therapeutic area (MeSH) Leukemia, Hairy Cell Anatomical therapeutic chemical (ATC) code L01BB04

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Litak is indicated for the treatment of hairy-cell leukaemia.

## Authorisation details

EMA product number EMEA/H/C/000504 Marketing authorisation holder

Lipomed GmbH

Hegenheimer Strasse 2

Marketing authorisation issued 14/04/2004 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Litak : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (172.66 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 03/04/2025

[View](/en/documents/procedural-steps-after/litak-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Litak-H-C-PSUSA-00000787-202402 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation - Annex I

English (EN) (18.64 KB - PDF)

**First published:** 03/04/2025

[View](/en/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_en.pdf)

[Other languages (25)](#file-language-dropdown-422)

български (BG) (79.22 KB - PDF)

**First published:**

03/04/2025

[View](/bg/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_bg.pdf)

español (ES) (18.73 KB - PDF)

**First published:**

03/04/2025

[View](/es/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_es.pdf)

čeština (CS) (85.64 KB - PDF)

**First published:**

03/04/2025

[View](/cs/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_cs.pdf)

dansk (DA) (18.33 KB - PDF)

**First published:**

03/04/2025

[View](/da/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_da.pdf)

Deutsch (DE) (23.81 KB - PDF)

**First published:**

03/04/2025

[View](/de/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_de.pdf)

eesti keel (ET) (15.21 KB - PDF)

**First published:**

03/04/2025

[View](/et/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_et.pdf)

ελληνικά (EL) (76.53 KB - PDF)

**First published:**

03/04/2025

[View](/el/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_el.pdf)

français (FR) (23.95 KB - PDF)

**First published:**

03/04/2025

[View](/fr/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_fr.pdf)

hrvatski (HR) (80.83 KB - PDF)

**First published:**

03/04/2025

[View](/hr/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_hr.pdf)

íslenska (IS) (19.97 KB - PDF)

**First published:**

03/04/2025

[View](/is/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_is.pdf)

Gaeilge (GA) (18.87 KB - PDF)

**First published:**

03/04/2025

[View](/ga/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_ga.pdf)

italiano (IT) (20.35 KB - PDF)

**First published:**

03/04/2025

[View](/it/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_it.pdf)

latviešu valoda (LV) (81.31 KB - PDF)

**First published:**

03/04/2025

[View](/lv/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_lv.pdf)

lietuvių kalba (LT) (82.32 KB - PDF)

**First published:**

03/04/2025

[View](/lt/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_lt.pdf)

magyar (HU) (80.95 KB - PDF)

**First published:**

03/04/2025

[View](/hu/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_hu.pdf)

Malti (MT) (90.75 KB - PDF)

**First published:**

03/04/2025

[View](/mt/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_mt.pdf)

Nederlands (NL) (20.14 KB - PDF)

**First published:**

03/04/2025

[View](/nl/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_nl.pdf)

norsk (NO) (23.51 KB - PDF)

**First published:**

03/04/2025

[View](/no/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_no.pdf)

polski (PL) (84.83 KB - PDF)

**First published:**

03/04/2025

[View](/pl/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_pl.pdf)

português (PT) (19.7 KB - PDF)

**First published:**

03/04/2025

[View](/pt/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_pt.pdf)

română (RO) (79.71 KB - PDF)

**First published:**

03/04/2025

[View](/ro/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_ro.pdf)

slovenčina (SK) (85.39 KB - PDF)

**First published:**

03/04/2025

[View](/sk/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_sk.pdf)

slovenščina (SL) (80.93 KB - PDF)

**First published:**

03/04/2025

[View](/sl/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_sl.pdf)

Suomi (FI) (18.65 KB - PDF)

**First published:**

03/04/2025

[View](/fi/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_fi.pdf)

svenska (SV) (18.27 KB - PDF)

**First published:**

03/04/2025

[View](/sv/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation-annex-i_sv.pdf)

Litak-H-C-PSUSA-00000787-202402 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/118109/2025

English (EN) (140.4 KB - PDF)

**First published:** 03/04/2025

[View](/en/documents/scientific-conclusion/litak-h-c-psusa-00000787-202402-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Litak : EPAR - Procedural steps taken before authorisation

English (EN) (105.59 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/procedural-steps/litak-epar-procedural-steps-taken-authorisation_en.pdf)

Litak : EPAR - Scientific Discussion

English (EN) (407.71 KB - PDF)

**First published:** 21/10/2005

**Last updated:** 21/10/2005

[View](/en/documents/scientific-discussion/litak-epar-scientific-discussion_en.pdf)

#### More information about Litak

This product is no longer an orphan medicine. It was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu301055) on 18 September 2001. Litak was removed from the Community register of orphan medicinal products in April 2014 at the end of the 10-year period of market exclusivity.

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 03/04/2025

## Share this page

[Back to top](#main-content)